tirzepatide grand junction co Compounded in Colorado (CO) Medical Weight Loss | Bare
Description
Compounded in an FDA-inspected facility
Tirzepatide has demonstrated unprecedented efficacy for A1c lowering and weight loss in clinical trials and was approved by the FDA in May 2022 as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
In the absence of a headtohead comparison, these findings may help to guide clinician decisions and enable pharmacoeconomic assessment of the most suitable incretinbased treatment for patients with T2D
Check out the best online weight-loss clinics
A 10mg/ml vial contains 2.5mg in those 25 units
